Mackenzie Financial Corp Raises Stock Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Mackenzie Financial increased its stake in Intuitive Surgical by 6.1% in Q3 and now owns 263,013 shares worth about $117.6 million (≈0.07% of the company), indicating continued institutional buying interest.
• Intuitive reported a strong quarter (EPS $2.53 vs. $2.27 est.; revenue $2.87B, up 18.8%) and has seen several analyst upgrades and higher price targets—Citi upgraded to Buy—with a consensus target near $616, supporting near‑term momentum.
• Offsetting the positives, insiders have sold roughly 37,907 shares (~$20M) in the last 90 days (including a director sale of 24,500 shares), leaving insiders with about 0.70% ownership, which may weigh on sentiment.

Mackenzie Financial Corp lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,013 shares of the medical equipment provider's stock after purchasing an additional 15,065 shares during the quarter. Mackenzie Financial Corp owned about 0.07% of Intuitive Surgical worth $117,627,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tobam increased its stake in Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider's stock worth $25,000 after buying an additional 40 shares during the period. Kilter Group LLC acquired a new stake in Intuitive Surgical during the 2nd quarter worth approximately $27,000. Greykasell Wealth Strategies Inc. purchased a new position in Intuitive Surgical in the 3rd quarter valued at approximately $27,000. Caitlin John LLC acquired a new position in shares of Intuitive Surgical in the third quarter worth $30,000. Finally, Guerra Advisors Inc acquired a new position in shares of Intuitive Surgical in the third quarter worth $37,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Citi upgraded ISRG to Buy and set a $590 price target, calling out resilient med‑tech fundamentals — a clear near‑term catalyst that likely pushed buying interest. Read More.
• Positive Sentiment: Analyst coverage and commentary emphasize product momentum (da Vinci 5, Ion and SP platforms) and procedure growth, supporting revenue and recurring‑revenue visibility into 2026. Read More.
• Positive Sentiment: Intuitive closed the acquisition of regional da Vinci and Ion distribution businesses, consolidating distribution and potentially improving margin/recurring revenue capture. Read More.
• Neutral Sentiment: Seeking Alpha reiterated the company’s strong moat and solid Q4 results but flagged valuation (P/E ~63 vs. historical ~53) and recommended a Hold — this tempers upside for value‑oriented investors. Read More.
• Neutral Sentiment: MarketWatch noted ISRG outperformed peers on a strong trading day, reflecting today’s buying interest but not adding new fundamental news. Read More.
• Neutral Sentiment: MarketBeat’s roundup reiterates broad analyst support and a consensus target near $616, underpinning a constructive longer‑term view but noting mixed ratings (Buy/Hold). Read More.
• Negative Sentiment: Insider selling: multiple recent sales by senior executives (SVP Mark Brosius and EVP Myriam Curet) have been disclosed; while common for compensation/liquidity reasons, clustered insider sales can weigh on sentiment. Read More.

Insider Activity

In other news, Director Gary S. Guthart sold 24,500 shares of the firm's stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $530.10, for a total transaction of $12,987,450.00. Following the sale, the director owned 3,694 shares of the company's stock, valued at approximately $1,958,189.40. This trade represents a 86.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark Brosius sold 4,500 shares of the business's stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $547.36, for a total value of $2,463,120.00. Following the sale, the senior vice president owned 907 shares of the company's stock, valued at approximately $496,455.52. The trade was a 83.23% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 37,907 shares of company stock worth $19,997,187. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Trading Up 1.4%

Intuitive Surgical stock opened at $492.87 on Thursday. The company has a fifty day simple moving average of $516.79 and a 200-day simple moving average of $512.60. The stock has a market cap of $175.03 billion, a P/E ratio of 62.47, a price-to-earnings-growth ratio of 3.75 and a beta of 1.66. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating the consensus estimate of $2.27 by $0.26. The firm had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.Intuitive Surgical's revenue for the quarter was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.21 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Royal Bank Of Canada increased their price objective on Intuitive Surgical from $625.00 to $650.00 and gave the company an "outperform" rating in a research note on Wednesday, December 17th. Robert W. Baird lowered their target price on Intuitive Surgical from $655.00 to $645.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. TD Cowen upgraded Intuitive Surgical to a "strong-buy" rating in a report on Tuesday, January 27th. HSBC increased their price target on Intuitive Surgical from $644.00 to $653.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Finally, BTIG Research reiterated a "buy" rating and issued a $616.00 price objective on shares of Intuitive Surgical in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $615.86.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. Intuitive's business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.